Company / SG&A Expense
Thermo Fisher Scientific SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$8.7B
FY2025
5-year range
$6.1B / $8.7B
FY2021-FY2025
Trend
+1.6%
vs FY2024
Sector context
#9 of 158
Health Care
What the data says
Among 158 Health Care companies, Thermo Fisher Scientific is in the bottom 6% for sg&a expense. SG&A Expense has increased for 4 consecutive years, from $6.1B in FY2021 to $8.7B in FY2025.
Based on SEC 10-K filings.
$8.7B in FY2025 with a 5-year CAGR of +4.7%. Top quartile in the Health Care sector.
Increased from $8.0B to $8.7B over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +8.0%
- 5-Year CAGR
- +4.7%
- 10-Year CAGR
- -
Sector benchmark
Bottom 6% in Health CareTop 94% of 158This company $8.7B Sector average $175.9B
▼
-95.0% below sector average
Key checks
Key Insights
- Thermo Fisher Scientific's sg&a expense has grown for 4 consecutive years.
- 5-year CAGR of +4.7%, indicating consistent growth.
- In FY2025, sg&a expense increased 1.6% year-over-year.
- Ranks #9 out of 158 companies in the Health Care sector.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $8.7B | +1.6% |
| FY2024 | $8.6B | +7.3% |
| FY2023 | $8.0B | +15.5% |
| FY2022 | $6.9B | +12.8% |
| FY2021 | $6.1B | -11.3% |
| FY2020 | $6.9B | +12.8% |
| FY2019 | $6.1B | +1.4% |
| FY2018 | $6.1B | +10.0% |
| FY2017 | $5.5B | +10.7% |
| FY2016 | $5.0B | +7.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026